Thomas E Januario from 315 Precita Ave, San Francisco, CA 94110, age 56

Us Patents

Selecting Patients For Therapy With A Her Inhibitor
view source
US Patent:

20060121044, Jun 8, 2006
Filed:

Dec 6, 2005
Appl. No.:

11/295229
Inventors:

Lukas Amler - Foster City CA, US
Thomas Januario - San Francisco CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

C12Q 1/68
A61K 39/395
US Classification:

424155100, 435006000
Abstract:

A method for selecting patients for therapy with a HER inhibitor, such as pertuzumab, based on gene expression analysis is described. A method for assessing HER phosphorylation or activation in a biological sample via gene expression analysis is also described.

Biomarkers And Methods For Determining Sensitivity To Epidermal Growth Factor Receptor Modulators
view source
US Patent:

20060234237, Oct 19, 2006
Filed:

Jan 8, 2004
Appl. No.:

10/541749
Inventors:

Lukas Amler - Foster City CA, US
Thomas Januario - San Francisco CA, US
International Classification:

C12Q 1/68
G01N 33/574
US Classification:

435006000, 435007230
Abstract:

EGFR biomakers useful in a method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) exposing the mammal to the EGFR modulator and (b) measuring in the mammal level of at least one biomaker, wherein a difference in the level in at least one biomaker measured in (b) compared to the level of the biomaker in a mammal that has not been exposed to the EGFR modulator indicates that the mammal will respond therapeutically to the method of treating cancer.

Selecting Patients For Therapy With A Her Inhibitor
view source
US Patent:

20080317753, Dec 25, 2008
Filed:

May 1, 2008
Appl. No.:

12/113802
Inventors:

LUKAS C. AMLER - Foster City CA, US
THOMAS E. JANUARIO - San Francisco CA, US
Assignee:

GENENTECH, INC. - SOUTH SAN FRANCISCO CA
International Classification:

A61K 39/395
A61K 38/18
A61P 35/00
C12Q 1/48
C12Q 1/02
US Classification:

4241381, 435 15, 435 29
Abstract:

A method for selecting patients for therapy with a HER inhibitor, such as pertuzumab, based on gene expression analysis is described. A method for assessing HER phosphorylation or activation in a biological sample via gene expression analysis is also described.

Mutant Smoothened And Methods Of Using The Same
view source
US Patent:

20120282259, Nov 8, 2012
Filed:

Sep 2, 2010
Appl. No.:

13/394069
Inventors:

Frederic J. de Sauvage - Foster City CA, US
Gerrit J.P. Dijkgraaf - San Francisco CA, US
Thomas Januario - San Francisco CA, US
Robert L. Yauch - Redwood City CA, US
Assignee:

Curis, Inc - Lexington MA
Genentech, Inc - San Francisco CA
International Classification:

C07K 14/705
C07H 21/04
C12Q 1/68
G01N 33/566
A61K 31/496
C07K 16/30
A61K 39/395
A61P 35/00
A61K 31/167
A61K 31/4545
C12N 15/12
G01N 21/76
US Classification:

4241391, 536 235, 536 2431, 435 611, 435 723, 435 613, 530350, 5303879, 5303873, 5303917, 514618, 514318, 51425313
Abstract:

The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, we describe a mutation in the serpentine receptor, Smoothened (SMO), which results in resistance to a Hedgehog (Hh) pathway inhibitor in medulloblastoma. A single amino acid substitution in a conserved aspartic acid residue of SMO maintains Hh signaling, but results in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. This mutation was not only acquired in a GDC-0449-resistant mouse model of medulloblastoma, but was identified in a Medulloblastoma patient following relapse on GDC-0449. The invention provides screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance.

Diagnostic Markers
view source
US Patent:

20130084286, Apr 4, 2013
Filed:

Aug 30, 2012
Appl. No.:

13/599611
Inventors:

Thomas E. Januario - San Francisco CA, US
David Shames - San Francisco CA, US
International Classification:

C12Q 1/68
US Classification:

4241331, 435 611, 5142664, 4241421
Abstract:

The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.

Diagnostic And Therapeutic Methods For Cancer
view source
US Patent:

20210338684, Nov 4, 2021
Filed:

Jul 8, 2021
Appl. No.:

17/370721
Inventors:

- South San Francisco CA, US
Xiaofen YE - Foster City CA, US
Thomas E. JANUARIO - San Francisco CA, US
International Classification:

A61K 31/5377
A61P 35/00
A61K 45/06
C12Q 1/6886
Abstract:

The present invention provides diagnostic and therapeutic methods for cancer. The invention provides methods of determining whether a patient having a cancer is likely to respond to treatment comprising an inhibitor of H3K27 methylation, methods of predicting responsiveness of a patient having a cancer to treatment comprising one or more inhibitors of H3K27 methylation, methods of selecting a therapy for a patient having a cancer, and methods of treating cancer based on expression levels of biomarkers of the invention (e.g., the expression level of SMARCA2 or the occupancy level of H3K27 at a SMARCA2 promoter).

Mutant Smoothened And Methods Of Using The Same
view source
US Patent:

20160313354, Oct 27, 2016
Filed:

Apr 15, 2016
Appl. No.:

15/130223
Inventors:

- Lexington MA, US
- South San Francisco CA, US
Thomas Januario - San Francisco CA, US
Robert L. Yauch - Redwood City CA, US
International Classification:

G01N 33/74
Abstract:

The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, we describe a mutation in the serpentine receptor, Smoothened (SMO), which results in resistance to a Hedgehog (Hh) pathway inhibitor in medulloblastoma. A single amino acid substitution in a conserved aspartic acid residue of SMO maintains Hh signaling, but results in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. This mutation was not only acquired in a GDC-0449-resistant mouse model of medulloblastoma, but was identified in a Medulloblastoma patient following relapse on GDC-0449. The invention provides screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance.